Articles tagged with Platelets
Researchers create first three-dimensional tissue system that reproduces human bone marrow and generates functional human platelets. The system provides a laboratory model for studying blood disorders and predicting drug efficacy, with potential applications in regenerative medicine and patient-specific treatments.
A study comparing two transfusion strategies for patients with severe trauma found that a balanced ratio of plasma, platelets, and red blood cells resulted in fewer deaths from exsanguination and improved hemostasis within 24 hours. No significant differences were observed in overall mortality at 24 hours or 30 days.
A new LA BioMed study found that platelet transfusions and DDAVP are not effective in preventing further bleeding or death in patients with traumatic brain injuries. The researchers analyzed data from 408 patients and found no significant differences in mortality or hemorrhage progression between those who received the treatments and t...
Researchers at CNIO have discovered a new way to produce platelets artificially, reprogramming megakaryocytes to increase in size. This breakthrough could lead to the development of new treatments for thrombocytopenia and cancer by targeting specific proteins involved in cell growth.
A nationwide study found that platelet transfusions in rare blood cell disorders increase the risk of arterial clots and mortality. For thrombotic thrombocytopenic purpura (TTP) and heparin-induced thrombocytopenia (HIT), these transfusions are associated with a fivefold to sixfold increase in death odds.
Bio-inspired bleeding control is achieved through the synthesis of platelet-like nanoparticles that mimic the human body's own coagulation processes. These tiny particles can be added to blood flow to supply or augment the patient's natural platelet supply, stemming bleeding and initiating healing.
A new set of guidelines for platelet transfusion aims to reduce bleeding in adult patients, while a multidrug regimen shows higher remission rates for lupus nephritis patients in a randomized controlled trial.
Researchers have developed artificial platelet-like nanoparticles that combine morphological, mechanical, and surface chemical properties of natural platelets. These artificial platelets can simulate natural platelets' ability to collide with red blood cells, enabling selective clot formation at vascular injury sites.
Researchers at Emory University discovered that platelets can 'feel' their environment and respond by increasing stickiness, leading to the formation of clots. Modifying material stiffness could reduce clot formation in medical devices.
Researchers discovered that the STXBP5 gene influences blood clotting by regulating VWF, a key contributor to normal clot formation. However, they found that mice lacking this gene experienced increased bleeding instead of clotting, highlighting distinct roles for STXBP5 in endothelial cells and platelets.
Researchers developed synthetic platelet-like particles that can augment natural blood clotting, potentially reducing trauma-related bleeding deaths. The particles were tested in animal models and human blood, showing effectiveness in slowing bleeding without causing adverse effects.
Researchers developed a scalable, next-generation platelet bioreactor to generate fully functional human platelets in vitro. The breakthrough addresses blood transfusion needs and has several advantages over conventional donor-derived platelets.
Researchers have developed nanoparticles that increase survival rates and show no signs of interference in healing after blast trauma. The artificial platelets, called hemostatic nanoparticles, were found to be effective in stopping bleeding and increasing survival rates.
International study reveals blood product sterilization processes can prevent platelets from carrying out their functions correctly, potentially leading to hemorrhages. The processes alter the genetic material of pathogen-reducing treatments, depleting platelets of RNA and impairing their ability to synthesize essential proteins.
Researchers have taken 'snapshots' of a critical receptor involved in blood coagulation, paving the way for novel, reversible blood-thinning substances. These new therapies aim to provide more effective control over platelet aggregation, reducing side effects and improving patient outcomes.
Melbourne researchers solved a puzzle on how an essential hormone stimulates platelet production. They found that bone marrow cells can become overstimulated and produce too many platelets, leading to blood diseases such as essential thrombocythemia.
Scientists at Case Western Reserve University have discovered how MRP-14 generates dangerous clots that could trigger heart attack or stroke. MRP-14 binds to a platelet receptor called CD36 to activate platelets, promoting pathologic blood clotting.
A new study published in Blood journal found that adhering to a Mediterranean diet is associated with lower levels of platelets and white blood cells, two markers of inflammation. This eating plan is linked to reduced inflammation and heart disease risk, particularly among healthy individuals.
Researchers aim to create artificial platelets that can stick to injury sites and signal natural platelets to home in on them, offering a potential solution to bleeding disorders. The technology has broad applications in stanching bleeding and detecting diseases.
Researchers have found a way to create platelets without donated blood, potentially solving supply shortages and ensuring treatments for all who need them. The new method involves deriving functional platelets from human induced pluripotent stem cells, offering an alternative to traditional blood donations.
Researchers at Cincinnati Children's Hospital Medical Center have successfully treated mouse models of Hurler syndrome with gene therapy delivered via platelets and bone marrow cells. The treatment resulted in complete metabolic correction of the disease, normalizing IDUA levels in peripheral organs.
Researchers discovered a novel clot structure involving polyhedrocytes in contracted clots, making them less responsive to medications. T2HemoStat enabled the detection of this unique structure, which could lead to better diagnostic tools and therapeutic choices.
Researchers at Penn Medicine discovered a new shape of red blood cells when they are compressed during clot formation. The polyhedral structures, also known as polyhedrocytes, are tightly packed within the clot interior and may help explain why clots develop resistance to thrombolytic agents.
Researchers identify novel genetic mutations in the CALR gene that are common in patients with myeloproliferative neoplasms, improving diagnosis and treatment decisions. The study also explores the use of lenalidomide and idelalisib to strengthen rituximab treatment for pre-treated patients.
A study published in the Journal of Clinical Investigation reveals that type 2B von Willebrand disease is associated with platelet dysfunction. Researchers found that a mutation in the von Willebrand factor protein can inhibit platelet activation and promote thrombocytopathy.
Northwestern University researchers have developed a new technique to profile enzyme activities in cell lysate, providing a fast, low-cost, and label-free method for studying post-transcriptional processes. By using peptide arrays and SAMDI mass spectrometry, the researchers were able to identify patterns of enzyme activities and shed ...
Taking aspirin at bedtime instead of in the morning could reduce acute heart events by reducing platelet activity. A randomized study found that taking aspirin at bedtime resulted in a 22-unit reduction in platelet activity compared to taking it in the morning.
Researchers found that platelets activate a screening process allowing lymphocytes to exit the bloodstream without causing bleeding. This discovery opens avenues for further research into the role of platelets in vascular health and inflammation.
Researchers have identified a potential new angle for drug development in preventing thrombosis, a dangerous blood clot that can lead to stroke and heart attack. The study uncovered a key platelet protein that could be exploited to develop drugs that keep platelets from forming pathological clots.
New research finds that a subpopulation of immune cells, known as T lymphocytes, have platelets bound to their surface, reducing activation and proliferation. This discovery opens the door to potential treatments targeting platelet binding to lymphocytes.
Dr. Andrew S. Weyrich receives the 2013 William Dameshek Prize for his seminal work on the cellular and molecular causes of blood clots, revolutionizing our understanding of platelet function. His research has far-reaching implications in hematology and beyond.
Kenneth Kaushansky and David J. Kuter are honored with the 2013 Ernest Beutler Lecture for their significant advances in thrombopoietin, a growth factor regulating platelet production. Drs. Kaushansky and Kuter will present their lecture on December 9 at the 55th ASH Annual Meeting.
High platelet reactivity after drug-eluting stent implantation was associated with increased risk of stent thrombosis and heart attack, while also reducing major bleeding. However, the association between high platelet reactivity and mortality was not independent.
Researchers from Max Planck Institute discovered the P2Y2 receptor molecule on blood platelet walls enables tumor cells to enter organs via blood vessel openings. Blocking this key molecule may lead to new therapeutic approaches for malignant tumors.
Researchers at the University of Calgary found that platelets actively search for specific bacteria and seal them off from the body, reducing the risk of infection. This mechanism is crucial in combating harmful bacteria like MRSA, which can lead to serious conditions.
Researchers find genetic diversity as key to the species' adaptive potential, global distribution, and ability to thrive in various ocean environments. The study reveals a pan-genome with a core set of genes supplemented by region-specific genes, enabling the calcified alga to live almost everywhere at the ocean surface.
Scientists have created a composite material that can bend and twist in response to external stimuli like temperature or moisture. This programmable plasticity enables the material to take on various shapes, making it suitable for applications such as self-shaping ceramic parts and biodegradable implants.
Researchers at Rice University and Baylor College of Medicine have discovered that stressed proteins can remain in a dangerous shape for up to five hours before returning to their normal state. This finding has profound clinical implications, as it helps explain the workings of the key clot-forming protein von Willebrand factor.
Researchers are developing artificial blood platelets laced with regulatory chemicals that can be injected into the bloodstream to control bleeding and promote healing. The synthetic platelets have shown promise in animal models, reducing clotting time by approximately 30 percent.
A team of researchers at the University of Pennsylvania School of Medicine has identified a powerful new weapon against malaria by mimicking a natural defense found in human blood platelets. They discovered that a synthetic molecule, PMX1207, targets and destroys the parasite's digestive vacuole, killing it without harming the host cell.
A large registry study found that patients with low levels of platelet inhibition after receiving a drug-eluting stent are at higher risk for blood clots and heart attacks. However, this responsiveness to clopidogrel was also linked to reduced bleeding complications.
Patients with clopidogrel non-responsiveness had a higher risk of stent thrombosis and acute coronary syndrome. Personalized antiplatelet treatment using platelet function testing shows promise in reducing ischemic events without increasing bleeding risks.
A study found that personalized antiplatelet treatment using platelet function testing improved clinical outcomes in patients undergoing percutaneous coronary intervention. Non-responders to clopidogrel were given higher doses or alternative therapies, reducing stent thrombosis and acute coronary syndrome rates.
The RECLOSE 2-ACS study found that approximately 20% of patients had a high platelet reactivity to aspirin and were nonresponders. These patients had a significantly higher prevalence of an ischemic event or cardiac death at the 2 year follow-up.
The study found that global platelet reactivity is a significant predictor of ischemic events in patients with acute coronary syndrome (ACS) who are at high risk. Patients who do not respond to clopidogrel therapy have a higher prevalence of adverse cardiovascular events, including ischemic events and cardiac death.
Dr. James George is recognized for his pioneering work on platelet glycoproteins, diagnosis and clinical management of idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP). He has also made significant contributions to education, research, and practice through various initiatives.
Researchers found that adding vorapaxar to standard antiplatelet therapy significantly reduces the long-term risk of recurrent cardiovascular events in patients with a prior heart attack. The study, published in the Lancet, showed a 20% reduction in cardiovascular death, heart attack, or stroke.
A study published by the European Society of Cardiology found that passive smoking increases platelet activation and carbon monoxide levels in healthy individuals. The researchers investigated three parameters: mean platelet volume (MPV), carboxyhemoglobin (COHb), and lactate.
Dr Kylie Mason's research on BH3-mimetics and platelets reveals a molecular 'clock' that dictates their lifespan. Her work has implications for diagnosis and treatment of disorders affecting platelets, as well as blood bank storage.
Researchers have made progress toward a portable emergency treatment for stopping life-threatening internal bleeding. Synthetic platelets, artificial versions of blood's natural clotting particles, are being developed to quickly and efficiently form clots at internal wounds, increasing survival rates in laboratory tests.
Researchers at Case Western Reserve University developed synthetic platelets that double the survival rate of internal injury victims in the first hour after injection. The nanoparticles work by creating healthy clots and binding to natural platelets to form larger clots, reducing bleeding time.
Researchers at the University of Utah will investigate the molecular causes of blood clots, which threaten millions of people worldwide. The center aims to apply basic science to find new diagnostic and therapeutic measures for thrombosis, making them available to patients rapidly.
A new clinical study by the National Heart, Lung, and Blood Institute found that eltrombopag improved blood cell production in 11 out of 25 participants with severe aplastic anemia. The drug was well-tolerated, with few side effects, and six patients showed significant improvements in all three types of blood cells.
Researchers at UC Santa Barbara developed synthetic platelets with unique physical and biochemical properties to mimic natural platelets. These particles could be used for various biomedical applications, including wound healing, targeting damaged blood vessels, or delivering drugs that dissolve blood clots.
Researchers developed a mathematical model predicting the final size and shape of platelets, which form blood clots. The study provides insights into the forces inside cells that turn into platelets, shedding light on a longstanding puzzle in platelet formation.
In a new analysis, rituximab shows promising results in treating chronic immune thrombocytopenic purpura (ITP), a bleeding disorder that destroys blood cells. The treatment promotes long-term response in approximately one quarter of patients, with normalized platelet counts lasting at least five years.
Researchers at the University of Delaware have found that the JAM-A protein helps prevent unwanted blood clots, which are a major contributor to heart disease and stroke. The study suggests that the protein may serve as a biomarker for predicting risk of these conditions.
Researchers created a virtual copy of patient-specific blood to simulate blood clotting and test the effectiveness of drugs like aspirin. The simulations predicted accurate responses to drugs in individual donors, identifying potential genetic mutations.
Researchers at Penn Medicine caution against blocking the effects of PGD2 on DP1 in patients prone to cardiovascular disease, particularly those taking niacin. This is due to concerns that it may enhance platelet activation and lead to increased risk of heart attacks.
Scientists have discovered that the platelet activating factor receptor plays a crucial role in graft-versus-host disease, which can cause significant tissue damage and mortality. Blocking this receptor may lead to reduced tissue injury and improved survival rates for patients undergoing bone marrow transplants.